RELAPSE PREVENTION IN SCHIZOPHRENIA AND RELATED PSYCHIATRIC DISORDERS:
Promoting Recovery through Improved Adherence

Credit Area For Credit: Register/Login     View Activity As Guest




Release Date: Oct 15, 2015          Expiration Date: Oct 15, 2016



By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.


SUPPLEMENTAL  Slides


<a href="/Uploads/Programs/171/Documents/3729_StrokeRTSlides_Final.pdf" onclick="return false;" target="_blank" re_target="_blank" re_onclick="function onclick() { return false; }">Download (PDF)Click here for a PDF of supplemental slides that accompany this webcourse. <a href="/Uploads/Programs/171/Documents/3729_StrokeRTSlides_Final.pdf" onclick="return false;" target="_blank" re_target="_blank" re_onclick="function onclick() { return false; }">Download (PDF)


PRESENTATION SLIDES


Download (PDF) Click here to download a PDF of the program slides.

Program overview


Despite recent advances in the understanding and management of schizophrenia and schizoaffective disorder, these conditions remain chronic relapsing and remitting diseases associated with significant impairments in social and vocational functioning, as well as a shortened lifespan. Early initiation of treatment is believed to improve outcomes by catching these disorders when they are most responsive to treatment, when there is less psychosocial damage, and when treatments can possibly halt the neuroprogression that leads to pathophysiologic, symptomatic, and structural changes.

Unfortunately, considerable barriers to adequate early treatment exist, including delays in treatment initiation, inadequate prescriptions of antipsychotics, and a lack of patient adherence to treatment regimens. Relapse Prevention in Schizophrenia and Related Psychiatric Disorders is designed to help psychiatrists and other health care providers develop strategies to overcome these obstacles and improve the overall health and quality of life of their patients with schizophrenia and schizoaffective disorder.


Faculty



LESLIE CITROME, MD, MPH
Clinical Professor of Psychiatry and Behavioral Science
New York Medical College
Valhalla, NY

 

Read Biography


CHRISTOPH U. CORRELL, MD
Professor of Psychiatry
Hofstra Northwell School of Medicine
Medical Director, Recognition and Prevention Program
Zucker Hillside Hospital
Glen Oaks, NY

 

Read Biography

Target Audience


This activity is intended for psychiatrists, psychiatric nurses, allied health professionals, nurses, hospital-based pharmacists, NPs, PAs, and other health care providers who care for patients with schizophrenia and schizoaffective disorder.


Educational Objectives


At the conclusion of this activity, participants should be able to demonstrate the ability to:
  • Implement a collaborative care approach to patient management in schizophrenia and schizoaffective disorder to help remove barriers to patient adherence
  • Discuss the impact of psychosis relapse on the course of schizophrenia and schizoaffective disorder
  • Implement strategies to promote early treatment initiation and treatment adherence in patients with schizophrenia and schizoaffective disorder to improve long-term outcomes

Accreditation


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Cincinnati and Rockpointe. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


PHYSICIAN CREDIT DESIGNATION


The University of Cincinnati designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE INFORMATION

The University of Cincinnati adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by University of Cincinnati are required to disclose any relevant financial relationships with any commercial interest to University of Cincinnati as well as to learners. All conflicts of interest are identified and resolved by University of Cincinnati in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity. The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Leslie Citrome, MD, MPH: Consultant: Actavis (Forest), Alexza, Alkermes, Bristol-Myers Squibb, Eli Lilly, Forum, Genentech, Janssen, Jazz, Lundbeck, Merck, Medivation, Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva, Valeant; Speaker: Actavis (Forest), AstraZeneca, Janssen, Jazz, Lundbeck, Merck, Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva; Stock: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer

Christoph U. Correll, MD:
Advisory Board: Actavis, AbbVie, Genentech, IntraCellular Therapies, Lundbeck, Otsuka, Reviva, Roche, Sunovion, Supernus; Consultant: AbbVie, Actavis, Genentech, Gerson, IntraCellular Therapies, Janssen/Johnson & Johnson, Lehrman Group, Lundbeck, MedAvante, Medscape, Otsuka, Pfizer, ProPhase, Reviva, Roche, Sunovion, Supernus, Takeda; Speaker: Lundbeck, Otsuka, Takeda

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Carole Drexel, PhD, CHCP; Blair St. Amand; Jay Katz, CHCP; Susan P. Tyler; Rick Ricer, MD; Barbara Forney: Nothing to disclose


FDA Disclosure


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


System Requirements

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.


INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT


There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.  Participant is allowed to take the post-test three times.


Program Providers

 
Jointly provided by the University of Cincinnati and Rockpointe

Program Supporter


Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC

By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.